Xellia Pharmaceuticals Aps
http://xellia.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Xellia Pharmaceuticals Aps
Finance Watch: Alumis Launches IPO In Market Less Receptive Than Expected
Public Company Edition: Alumis grosses $250m after it planned to raise up to $317.7m in its IPO. Also, Zealand adds $1bn in a post-data offering, Tectonic and Eliem close $130.7m and $120m private placements to support recent mergers, and Ginkgo cuts 35% of its workforce.
Xellia CEO Questions Key Ingredients Reliance Of US And Europe
In an exclusive interview with Generics Bulletin, the CEO of API and FDF manufacturer Xellia Pharmaceuticals, expresses concern over supply chain resilience of the US and the EU, as he points out the weaknesses exposed by the pandemic. The company has also announced the release of its first anti-infectives manufactured at its newly operational Cleveland site.
When You Can’t Win For Losing: Kodak And The Reshoring Of US Pharmaceutical Manufacturing
Kodak, Fujifilm and startups Civica Rx and Phlow fight with grit, vision and government support to restore US pharmaceutical manufacturing.
Xellia Joins Medicines For Europe
With a commitment to make drug products affordable and accessible in Europe, Xellia has joined off-patent industry association Medicines for Europe.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Pharmaero
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice